Clinical Trials Logo

Filter by:
NCT ID: NCT04429256 Completed - Clinical trials for Mycobacterium Chimaera Infections

Prosthetic Valve and Graft Endocarditis With Mycobacterium Chimaera

Start date: April 10, 2020
Phase:
Study type: Observational

Mycobacterium chimaera infections have occurred in post-cardiac surgery patients in association with contaminated cardiac bypass heater-cooler devices. So far optimal therapeutical concepts are not clear. At the University Hospital Basel Mycobacterium chimaera- infected protheses are replaced to decrease pathogenic burden and to support antibiotic long- term treatment. This study is to analyze the efficacy of this therapeutic approach.

NCT ID: NCT04483908 Completed - COVID-19 Infection Clinical Trials

COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses

SEROBL-COVID19
Start date: April 10, 2020
Phase:
Study type: Observational

The study is to investigate the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland.

NCT ID: NCT04491994 Completed - Covid19 Clinical Trials

Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression

COVID-19
Start date: April 10, 2020
Phase: Phase 3
Study type: Interventional

Brief Summary: Purpose of this study is to evaluate efficacy of hydroxychloroquine (HCQ) in reducing progression of Corona Virus Disease 2019 (COVID - 19) and achieving viral clearance. Condition or disease :I COVID-19 ntervention/treatment :Drug: Hydroxychloroquine Sulfate Phase: Phase III

NCT ID: NCT04509414 Completed - Dexmedetomidine Clinical Trials

Intranasal Dexmedetomidine for Deep-sedated Pediatric Dental Patients

Start date: April 10, 2020
Phase: Phase 4
Study type: Interventional

It is important to choose an appropriate analgesia/sedation technique in pediatric dental treatment. Premedication combined with intravenous anesthesia is often used in deep sedation technique for pediatric dental treatment and it's a routine in most hospitals. Deep sedation has its unique advantages such as avoiding the airway damage with an enhanced recovery. Dexmedetomidine is suitable for intranasal mucosal administration as a premedication drug. It has been proved with several beneficial characteristics in other clinical procedures. This study intends to further explore the characteristics of nasal dexmedetomidine as premedication in pediatric oral treatment under deep sedation.

NCT ID: NCT04556604 Completed - Consent Clinical Trials

Surgical Consent During the COVID-19 Pandemic

Start date: April 10, 2020
Phase:
Study type: Observational

Multiloop audit of consenting practice in surgical procedures during the COVID-19 pandemic

NCT ID: NCT04625920 Completed - Infertility Clinical Trials

A Virtual Reality System for Pain and Anxiety Management During Outpatient Hysteroscopy

Start date: April 10, 2020
Phase: N/A
Study type: Interventional

To evaluate the effectiveness of VR as a distraction technique in the management of acute pain and anxiety during operative hysteroscopy in the outpatient setting.

NCT ID: NCT04837274 Completed - Clinical trials for Health Services Research

Anderson Study 1 - Tart Cherry Study

AS1
Start date: April 10, 2020
Phase: N/A
Study type: Interventional

The purpose of this study is to examine if tart cherry reduces food-induced elevations in serum uric acid.

NCT ID: NCT04879446 Completed - Bone Loss, Alveolar Clinical Trials

The Effect of Growth Factor on Implant Osseointegration

Start date: April 10, 2020
Phase: N/A
Study type: Interventional

In this study, concentrated growth factor obtained by centrifuging the patient's own blood and advanced platelet-rich fibrin liquids were applied to the implant cavity and surface. Thus, it was aimed to ensure that the osseointegration process would start earlier by ensuring a faster arrival of growth factor and healing mediators in the region, and thus, the time waited for the osseointegration process and the loading of the superstructure would be shortened. In this split-mouth study, a total of 32 patients including two separate study groups in different patients and a control group were included. While the CGF liquid was applied to the implant cavities and surfaces prepared in the study group of 16 patients, A-PRF liquid was applied to the study group of the other 16 patients. Conventional implant application was performed in the control groups of both groups. The torque values during the implantation were also recorded, and Resonance Frequency measurements were performed immediately after implantation with the Penguin RFA device and at postoperative weeks 2, 4, 6 and 12.

NCT ID: NCT05096039 Completed - Heart Failure Clinical Trials

Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models

Start date: April 10, 2020
Phase:
Study type: Observational

This study evaluated the association between sacubitril/valsartan utilization and HF patients' Part A & B expenditures within the reimbursement framework of BPCI and MSSP, and identified BPCI/MSSP participants with the greatest potential for performance improvement (with respect to improving quality and efficiency of care for HF patients) through optimized utilization of sacubitril/valsartan.

NCT ID: NCT05652114 Completed - Clinical trials for Emotional Regulation

Open Label Mightier Play in the Home

Start date: April 10, 2020
Phase: N/A
Study type: Interventional

Mightier is a digital mental health tool that uses video game-based heart rate biofeedback to teach emotion regulation. The primary goal of this study is to replicate results from original clinical trials, demonstrating that playing Mightier at home improves common symptoms associated with emotional dysregulation. Participants will be caregivers of children who are using Mightier, a video-game based heart rate biofeedback intervention. Caregivers will be asked to complete a short survey about their child's emotions and behaviors prior to their child's first play and then complete that survey two more times, at 8 weeks and 12 weeks post baseline. The pre-post self report design will allow us to observe changes during Mightier use and relate those changes to overall engagement with the intervention